Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas
- 29 August 2012
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 110 (2) , 279-285
Abstract
This study was conducted to assess the current pattern of use and the impact of available molecular predictive and prognostic biomarkers on clinical care in patients with glioblastoma (GBM). An online questionnaire consisting of 15 questions about the frequency of use and clinical utility of tissue-based molecular tests was distributed to 1,053 members of the Neuro-Oncology Community in the United States. A total of 320 responses (30.4 %) were collected. 73 respondents who did not see GBM patients were excluded from analysis. MGMT promoter methylation testing (MGMT-meth) was the most commonly requested (37.2; 95 % CI, 31–44), followed by EGFR amplification (22.7; 95 % CI, 18–28), co-deletion of 1p/19q (22.3 %), EGFR expression (21.5 %), P53 mutation (19.8 %), PTEN mutation or deletion (17.4 %), EGFRvIII mutation (12.1 %), IDH1/2 mutation (12.1 %), PDGFR (4.5 %), and PIK3CA (0.8 %). The perceived utility of these studies was variable between participants. A small percentage of respondents felt that any of the studies were “always” or “almost always” helpful in clinical decision making (MGMT-meth 10.9 %; range, 0–13.8 %), but more frequently “never” or “almost never” helpful (MGMT-meth 25.9 %; range, 25–54.7 %). 26.7 % reported not to routinely order any of these studies. Although molecular markers are frequently ordered for patients with GBM, only a minority of clinicians ordering these tests report that the results influence clinical decision-making. Molecular markers that are likely to affect patient care should be ordered with the goal to maximize benefit for patients and to avoid non-actionable results and additional costs.Keywords
This publication has 14 references indexed in Scilit:
- Controversies in the Adjuvant Therapy of High-Grade GliomasThe Oncologist, 2011
- Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastomaCancer, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT ActivityJournal of Clinical Oncology, 2008
- Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08Clinical Cancer Research, 2006
- Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsNew England Journal of Medicine, 2005
- Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptorBlood Cells, Molecules, and Diseases, 2005
- Chromosomal anomalies in oligodendroglial tumors are correlated with clinical featuresCancer, 2003
- Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.2000